Parabilis Medicines, Inc. Common Stock (PBLS) — Cash Flow-to-Debt Ratio
Parabilis Medicines, Inc. Common Stock (PBLS) has a Cash Flow-to-Debt Ratio of -0.35x as of March 2026, meaning its operating cash flow of $-49.20 Million could theoretically repay 0% of its total liabilities ($139.95 Million) in one year. For the full cash flow conversion analysis, see how efficiently does Parabilis Medicines, Inc. Common Stock generate cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Parabilis Medicines, Inc. Common Stock Cash Flow-to-Debt Ratio (2024–2025)
Historical debt coverage capacity for Parabilis Medicines, Inc. Common Stock across 2 annual periods. See Parabilis Medicines, Inc. Common Stock free cash flow to debt ratio to measure the company's free cash flow as a share of total liabilities.
Annual Cash Flow-to-Debt Ratio for Parabilis Medicines, Inc. Common Stock (2024–2025)
Year-by-year debt coverage analysis for Parabilis Medicines, Inc. Common Stock. See PBLS net working capital ratio to evaluate short-term liquidity relative to the company's equity base.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -1.27x | $-123.71 Million | $97.34 Million | ▼ -13.8% |
| 2024 | -1.12x | $-103.61 Million | $92.81 Million | — |